RXi Pharmaceuticals (RXII) has entered into a research collaboration with Iovance Biotherapeutics (IOVA) to evaluate the potential synergies with RXi’s novel sd-rxRNA therapeutic compounds and Iovance’s autologous cell therapy based on tumor-infiltrating lymphocytes for the use in the treatment of cancer. Synergies between RXi’s self-delivering RNAi therapeutic platform and Iovance’s TIL cell therapy approach will be explored preclinically.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.